Evaluation of specific T cell immune response to SARS-CoV-2 in COVID-19 infection and following Gam-COVID-Vac vaccine prophylaxis

Cover Page

Cite item

Full Text

Abstract

An aberrant immune response during SARS-CoV-2 infection has been shown to determine the clinical features, disease severity, and progression of COVID-19 infection. This work aimed for comprehensive assessment of the immune response by comparative evaluation of diagnostic significance of the antibodies to RBD domain of the SARS-CoV-2 spike protein, as well as detection of effector CD4+ and CD8+T cells specific to SARS-CoV-2 antigens. The study was performed in unvaccinated persons, healthy individuals vaccinated with Gam-COVID-Vac, and in the patients who have had COVID-19 infection. We have found that IgG antibodies to the RBD domain of the SARS-CoV-2 spike protein are detectable at a frequency of 73% to 92% of cases in vaccinated persons and COVID-19 reconvalescents. The numbers of effector CD4+ and CD8+T lymphocytes responding to stimulation with SARS-CoV-2 antigens by producing the IFNã cytokine varied depending on the introduced antigen and tended to be higher in vaccinated individuals. In non-vaccinated healthy persons who contacted with COVID-19 patients, T cell response to the SARS-CoV-2 nucleoproteins was revealed. For adequate assessment of antiviral and post-vaccination immune response to COVID-19, it would be necessary to study not only humoral immune response by the presence of antibodies, but also functionally active specific T lymphocytes directed for SARS-CoV-2 protein antigens.

About the authors

N. G. Plekhova

Pacific State Medical University

Author for correspondence.
Email: pl_nat@hotmail.com

PhD, MD (Biology), Associate Professor, Head, Central Research Laboratory

Russian Federation, Vladivostok

T. S. Sitdikova

Pacific State Medical University

Email: pl_nat@hotmail.com

PhD (Medicine), Lecturer, Department of Clinical Laboratory Diagnostics, General and Clinical Immunology

Russian Federation, Vladivostok

A. A. Dubiy

Pacific State Medical University

Email: olleariu.a@yandex.ru

Student, Faculty of Public Health

Russian Federation, Vladivostok

A. O. Mikhailov

Pacific State Medical University

Email: pl_nat@hotmail.com

PhD (Medicine), Research Associate, Central Research Laboratory

Russian Federation, Vladivostok

E. V. Prosekovа

Pacific State Medical University

Email: pl_nat@hotmail.com

PhD, MD (Medicine), Professor, Head, Department of Clinical Laboratory Diagnostics, General and Clinical Immunology

Russian Federation, Vladivostok

References

  1. Потеряев Д.А., Аббасова С.Г., Игнатьева П.Е., Стрижакова О.М., Колесник С.В., Хамитов Р.А. Оценка Т-клеточного иммунитета к SARS-CoV-2 у переболевших и вакцинированных против COVID-19 лиц с помощью ELISPOT набора ТиграТест® SARS-CoV-2 // БИОпрепараты. Профилактика, диагностика, лечение, 2021. Т. 21, № 3. С. 178-192. [Poteryaev D.A., Abbasova S.G., Ignatyeva P.E., Strizhakova O.M., Kolesnik S.V., Khamitov R.A. Assessment of T-cell immunity to SARS-CoV-2 in COVID-19 convalescents and vaccinated subjects, using TigraTest® SARS-CoV-2 ELISPOT kit. BIOpreparaty. Profilaktika, diagnostika, lechenie = BIOpreparations. Prevention, Diagnosis, Treatment, 2021, Vol. 21, no. 3, pp. 178-192. (In Russ.)]
  2. Bastos M.L., Tavaziva G., Abidi S.K., Campbell J.R., Haraoui L.P., Johnston J.C., Lan Z., Law S., MacLean E., Trajman A., Menzies D., Benedetti A., Ahmad K.F. Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. BMJ, 2020, Vol. 370, m2516. doi: 10.1136/bmj.m2516.
  3. Diao B., Wang C., Tan Y., Chen X., Liu Y., Ning L., Chen L., Li M., Liu Y., Wang G., Yuan Z., Feng Z., Zhang Y., Wu Y., Chen Y. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front. Immunol., 2020, Vol. 11, 827. doi: 10.3389/fimmu.2020.00827.
  4. Grifoni A., Weiskopf D., Ramirez S.I., Mateus J., Dan J.M., Moderbacher C.R., Rawlings S.A., Sutherland A., Premkumar L., Jadi R.S., Marrama D., de Silva A.M , Frazier A., Carlin A.F., Greenbaum J.A., Peters B., Krammer F., Smith D.M., Crotty S., Sette A. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell, 2020, 181, рр. 1489-1501.e15.
  5. Gudbjartsson D.F., Norddahl G.L., Melsted P., Gunnarsdottir K., Holm H., Eythorsson E., Arnthorsson A.O., Helgason D., Bjarnadottir K., Ingvarsson R.F., Thorsteinsdottir B., Kristjansdottir S., Birgisdottir K., Kristinsdottir A.M., Sigurdsson M.I., Arnadottir G.A., Ivarsdottir E.V., Andresdottir M., Jonsson F., Agustsdottir A.B., Stefansson K. Humoral Immune Response to SARS-CoV-2 in Iceland. N. Engl. J. Med., 2020, Vol. 383, no. 18, рр. 1724-1734.
  6. Habel J.R., Nguyen T.H.O., van de Sandt C.E., Juno J.A., Chaurasia P., Wragg K., Koutsakos M., Hensen L., Jia X., Chua B., Zhang W., Tan H.X., Flanagan K.L., Doolan D.L., Torresi J., Chen W., Wakim L.M., Cheng A.C., Doherty P.C., Petersen J., Kedzierska K. Suboptimal SARS-CoV-2-specific CD8+ T cell response associated with the prominent HLA-A*02:01 phenotype. Proc. Natl. Acad. Sci. USA, 2020, Vol. 117, рр. 24384-24391.
  7. Kedzierska K., Thomas P.G. Count on us: T cells in SARS-CoV-2 infection and vaccination. Cell Rep. Med., 2022, Vol. 3, no. 3, 100562. doi: 10.1016/j.xcrm.2022.100562.
  8. Le Bert N., Tan A.T., Kunasegaran K., Tham C., Hafezi M., Chia A., Chng M., Lin M., Tan N., Linster M., Chia W.N., Chen M.I., Wang L.F., Ooi E.E., Kalimuddin S., Tambyah P.A., Low J.G., Tan Y.J., Bertoletti A. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature, 2020, Vol. 584, no. 7821, рр. 457-462.
  9. Sekine T., Perez-Potti A., Rivera-Ballesteros O., Strålin K., Gorin J.B., Olsson A., Llewellyn-Lacey S., Kamal H., Bogdanovic G., Muschiol S., Wullimann D.J., Kammann T., Emgård J., Parrot T., Folkesson E., Karolinska COVID-19 Study Group, Rooyackers O., Eriksson L.I., Henter J.I., Sönnerborg A., Buggert M. Robust T Cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell, 2020, Vol. 183, no. 1, pp. 158-168.e14.
  10. Thevarajan, I., Nguyen, T.H.O., Koutsakos, M., Druce, J., Caly, L., van de Sandt, C.E., Jia, X., Nicholson, S., Catton, M., Cowie, B., Tong S.Y.C., Lewin S.R., Kedzierska K. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat. Med., 2020, Vol. 26, рр. 453-455.
  11. Weiskopf D., Schmitz K.S., Raadsen M.P., Grifoni A., Okba N.M.A., Endeman H., van den Akker J.P.C., Molenkamp R., Koopmans M.P.G., van Gorp E.C.M., Haagmans B.L., de Swart R.L. , Sette A., de Vries R.D. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci. Immunol., 2020, 5, eabd2071. doi: 10.1126/sciimmunol.abd2071.

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Figure 1. Result of a positive TigerTest® SARS-CoV-2 assay

Download (823KB)
3. Figure 2. Indicators of the number of effector CD4+ and CD8+ T lymphocytes according to the results of the Tigra-Test® SARSCoV-2 for healthy individuals not vaccinated and not infected by the COVID-19 (A), vaccinated with Gam-COVID-Vac and not infected by the COVID-19 (B), unvaccinated, infected by the COVID-19 (C), vaccinated, infected by the COVID-19 (D) unvaccinated, infected by the COVID-19, rehabilitation period (E), vaccinated, infected by the COVID-19, rehabilitation period (F)

Download (502KB)

Copyright (c) 2022 Plekhova N.G., Sitdikova T.S., Dubiy A.A., Mikhailov A.O., Prosekovа E.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies